Last reviewed · How we verify
NCT05636592
Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung Cancer
trial testing immunotherapy in Lung Cancer in 250 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2024
Quick facts
| Lead sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 15 October 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- immunotherapy — full drug profile →
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Who can join
Adults 18 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective observational study was designed to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in combination with statins compared with treatment with PD-1/PD-L1 inhibitors alone in advanced NSCLC patients. Participants will receive either immunotherapy + statin or immunotherapy until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05636592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of immunotherapy
Trials testing the same drug.
- NCT06599827 — Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC · Phase 2 · not yet recruiting
- NCT06218901 — Association of Psychological Distress in Patients With Lung Cancer · recruiting
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials
Trials by the same sponsor.
- NCT07336888 — A Study on the Application of Positive Psychological Counseling Based on "Dou Bao" Software in Patients With Post-stroke · NA · not yet recruiting
- NCT07375862 — Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostas · Phase 2 · not yet recruiting
- NCT07301437 — RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. · Phase 4 · not yet recruiting
- NCT07289750 — The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients · Phase 4 · not yet recruiting
- NCT07512791 — Effect of Bagua Auriculotherapy on Pain in Patients Undergoing Hysteroscopy · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05636592 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05636592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing